Ticker Hub
EXEL — AI Analysis & Sentiment
3 recent AI-generated analyses for EXEL. Sentiment and confidence insights updated continuously.
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Exelixis' positive Phase 3 subgroup analysis for CABOMETYX in neuroendocrine tumors suggests a significant clinical and commercial win, indicating ...
May 30, 2026Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis's collaboration with Merck for a pivotal Phase 3 trial of zanzalintinib is a significant positive catalyst. This partnership de-risks deve...
May 19, 2026Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
Exelixis demonstrated robust Q1 2026 financial performance with strong revenue and EPS growth, complemented by a new $750 million stock repurchase ...
May 5, 2026